Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- PMDA to Use Science Committee to Help Strengthen Review System: Executive Director Utsumi
July 5, 2012
- MHLW Approves 2 APIs Including Switch OTC Version of Allegra
July 5, 2012
- New Bar Code Labeling Rules to Take Effect for Oral, Topical Drugs from July 2015
July 3, 2012
- 18 Ethical APIs/35 Products Reported at PAC
July 3, 2012
- MHLW Approves 15 Products Including Inlyta and Tenelia
July 2, 2012
- Mandatory Generic Drug Use Still Impractical Due to People’s Lingering Distrust: MHLW
July 2, 2012
- MHLW Calls for Caution to Secondary Damage from Fainting After HPV Vaccination
June 29, 2012
- MHLW Proposes 2-Stage Discussions on Cost-Effective Assessment of Medical Technologies
June 29, 2012
- JPO Rules Actonel Patent Invalid; Ajinomoto Considering Appeal
June 29, 2012
- MHLW Talks to Drug Makers with Facilities Eligible for Exemption from Planned Power Outages
June 27, 2012
- Targets for Generic Drug Use Should Be Included in Medical Expenditure Optimization Plan: Mr Konishi of DPJ
June 26, 2012
- MHLW Orders Updates from Chugai Following Criticism for Reporting Deficiencies by Roche in US
June 26, 2012
- MHLW Approves 11 Products Including Additional Indication for Lyrica
June 26, 2012
- Median Review Time Down by About Half Since FY2007: PMDA
June 25, 2012
- Antipyretic/Analgesics Are Most Common Cause for Relief Benefits for Damage from ADRs: PMDA
June 25, 2012
- PMDA Adopts New Rule for Staff Re-Employment Effective This Month, No Uses Made Yet
June 25, 2012
- 166 Applications Received for Preliminary Interviews for Regulatory Strategy Consultation in First 9 Months: PMDA
June 25, 2012
- Claims of “Ineffective” Generics Might Be Due to Placebo Effect in Some Cases: Mr Yoshida of HIB
June 25, 2012
- MHLW to Strengthen Focus on Dementia with Budget Request for FY2013
June 22, 2012
- MHLW to Draft New Guidelines on Pharmacotherapy for Dementia
June 22, 2012
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…